With the 2012 Presidential election upon us, healthcare – both as a social service and essential sector of our economy – is once again a main pillar in the heated political debate. Ann Romney and Michelle Obama, both with a direct connection to Multiple Sclerosis, have opened up to campaign supporters in recent months about the effects of this debilitating disease.
In Part II of our special report on the state of companies operating in central nervous system disease in the public markets, we look at one of the most promising nanocap companies we believe is ready to skyrocket.
How can one optimally design a clinical trial program for a medical device for a FDA clearance/approval submission? OneMedRadio spoke with Dr. Vladimir Dragalin and Dr. Michael Feldstein of Aptiv Solutions to discuss the changing tides of medical device regulatory and the advantages of using an adaptive design trial.
OneMedForum NY 2012 was well received and the turnout met and exceeded expectations. Unlike the past several years, there is a higher level of optimism within the investment community, according to attendees. The crux of this optimism, of course, is the perceived greater flow of capital to microcap companies that the JOBS Act can provide.
Christine Jacobs, CEO of Theragenics, enlightened OneMedForum NY 2012 attendees on a categorical operational observation: while the number of employees represent a fair barometer of her company’s success, they also define her compliance costs. Jacobs and David Weild, former NASDAQ Vice Chair, discussed the evolving market landscape with the passing of the JOBS Act.
Epion Health announces a partnership with CaerVision to deploy tablets at the point of care. CaerVision has allocated $3.5 million dollars to this initiative.
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
Apricus Bio VP Edward Cox discusses the future of drug delivery technology in the rapidly expanding world of personalized medicine.
Copyright © 2024 | WordPress Theme by MH Themes